IP Library › Granted Patent US 9,090,680
Granted Patent B2
US 9,090,680 · App. 13/760,936 · Granted Jul 28, 2015

Antibodies that specifically bind to abeta oligomers and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,680
App. No.
13/760,936
Granted
Jul 28, 2015
Kind
B2
Abstract

The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.

Claims (83)

1. A method for treating cognitive impairment associated with Aβ accumulation in the brain of a subject, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

2. A method for treating Alzheimer's disease, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

3. A method for suppressing the progression of Alzheimer's disease, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

4. A method for suppressing senile plaque formation associated with Aβ accumulation in the brain of a subject, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

5. A method for suppressing Aβ accumulation, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

6. A method for neutralizing Aβ induced neurotoxicity, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

7. A method for inhibiting Aβ amyloid fibril formation, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

8. A method for neutralizing Aβ mediated synaptic toxicity, which comprises administering an antibody that binds to an Aβ oligomer as an active ingredient to a subject in need thereof, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

9. A method for detecting an Aβ oligomer, which comprises detecting an Aβ oligomer contained in a sample collected from a subject by contacting the sample with an antibody that binds to an Aβ oligomer, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

10. The method of claim 9 , wherein the sample is blood or cerebrospinal fluid.

11. A method of diagnosing a subject as suffering from or being at risk of developing Alzheimer's disease, which comprises:

(a) contacting a sample collected from the subject with an antibody that binds to an Aβ oligomer; and

(b) measuring the amount of Aβ oligomer in the sample, wherein the subject is determined to suffer from or be at a risk of developing Alzheimer's disease when the amount measured in (b) is higher than that of a healthy individual, wherein the antibody is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

12. A method of diagnosing a subject as suffering from or being at risk of developing Alzheimer's disease, which comprises:

(a) contacting a sample collected from the subject with an antibody that binds to an Aβ oligomer and an antibody that binds to an Aβ monomer; and

(b) measuring the ratio of Aβ oligomer to Aβ monomer in the sample, wherein the subject is determined to suffer from or be at a risk of developing Alzheimer's disease when the ratio measured in (b) is higher than that of a healthy individual, wherein the antibody that binds to an Aβ oligomer is selected from the group consisting of:

(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 81 and an L chain having the amino acid sequence of SEQ ID NO: 83;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3 and

an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(3) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH;

(4) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 87 as VL; and

(5) an antibody that comprises the H chain of (3) and the L chain of (4).

13. The method as in either claim 11 or claim 12 , wherein the sample is blood or cerebrospinal fluid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2024
From: IMMUNAS PHARMA, INC.
To: ONCOTHERAPY SCIENCE, INC.
Reel/Frame 069276/0718 →